Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
24.97
+0.20 (0.81%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Pelthos Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pelthos Therapeutics stock have an average target of 54.17, with a low estimate of 48 and a high estimate of 62. The average target predicts an increase of 116.94% from the current stock price of 24.97.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pelthos Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 4 | 4 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $50 | Buy | Initiates | $50 | +100.24% | Apr 1, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $62 | Buy | Maintains | $60 → $62 | +148.30% | Mar 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +140.29% | Mar 19, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $48 | Buy | Initiates | $48 | +92.23% | Feb 27, 2026 |
| Roth Capital | Roth Capital | Strong Buy Maintains $57 → $55 | Strong Buy | Maintains | $57 → $55 | +120.26% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
62.04M
from 16.80M
Increased by 269.41%
Revenue Next Year
113.27M
from 62.04M
Increased by 82.57%
EPS This Year
-9.76
from -23.04
EPS Next Year
-1.46
from -9.76
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 67.7M | 126.0M | ||||||
| Avg | 62.0M | 113.3M | ||||||
| Low | 55.3M | 99.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 302.8% | 103.1% | ||||||
| Avg | 269.4% | 82.6% | ||||||
| Low | 229.3% | 60.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -5.72 | 0.16 | |||
| Avg | -9.76 | -1.46 | |||
| Low | -13.01 | -2.49 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.